title: Local hypertrophic/hyperplastic changes of keratinizing squamous epithelium of pinna induced by concanavalin A and other immunomodulators in mice.
abstract: Intradermal administration of concanavalin A, a potent T-cell mitogen, into an ear lap resulted in activation of chondrogenesis and stimulation of epidermis proliferation. This proliferation is sometimes invasive in character (pearls and epidermal nests form in the underlying connective tissue) but never turns into true cancerous lesions. This reaction can be delayed, but not prevented, by the prostaglandin inhibitor indomethacin. Stimulation of epidermis proliferation was also caused by administration of other immunomodulators, such as carrageenan type IV, Moloney sarcoma development, and rarely in the course of GvHr, but to much lesser degree than with concanavalin A. It is suggested that the same growth factors, which are mediators of local chondrocyte stimulation, are also mediators of keratinocyte activation.
authors.affiliation: Department of Histology and Embryology, Institute of Biostructure, Medical Academy, Warsaw, Poland.
authors.forename: K
authors.initials: K
authors.lastname: Włodarski
authors.forename: M
authors.initials: M
authors.lastname: Luczak
authors.forename: R
authors.initials: R
authors.lastname: Galus
authors.forename: P
authors.initials: P
authors.lastname: Włodarski
mesh_terms: D000276:Adjuvants, Immunologic / Q000633:toxicity*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002351:Carrageenan / Q000633:toxicity; D019902:Chondrocytes / Q000187:drug effects* / Q000473:pathology; D003208:Concanavalin A / Q000633:toxicity*; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D004427:Ear Diseases / Q000139:chemically induced* / Q000473:pathology; D004428:Ear Neoplasms / Q000209:etiology / Q000517:prevention & control; D004431:Ear, External / Q000187:drug effects* / Q000473:pathology; D004817:Epidermis / Q000187:drug effects* / Q000473:pathology; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D005260:Female; D006087:Graft vs Host Reaction; D006965:Hyperplasia; D006984:Hypertrophy; D007213:Indomethacin / Q000627:therapeutic use; D015603:Keratinocytes / Q000187:drug effects* / Q000473:pathology; D007633:Keratins / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008808:Mice, Inbred CBA; D008811:Mice, Inbred DBA; D008813:Mice, Inbred ICR; D016513:Mice, SCID; D008980:Moloney murine sarcoma virus / Q000472:pathogenicity; D011230:Precancerous Conditions / Q000139:chemically induced* / Q000473:pathology; D012513:Sarcoma, Experimental / Q000209:etiology / Q000517:prevention & control; D016042:Transplantation, Heterotopic
chemical_list: D000276:Adjuvants, Immunologic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003208:Concanavalin A; D007633:Keratins; D002351:Carrageenan; D007213:Indomethacin